Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI could predict heart and artery risks before they happen

NCT ID NCT07187700

Knowledge-focused Sponsor: Amsterdam UMC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study will collect data from 1100 people with peripheral artery disease or abdominal aortic aneurysm across six European centers. Researchers will use artificial intelligence to analyze clinical data, blood samples, imaging, and wearable device information to build tools that predict disease progression and heart-related risks. The goal is to help doctors personalize treatment and reduce serious complications like heart attack or amputation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to AI tools that help doctors predict which patients are at high risk of complications, enabling earlier and more personalized treatment.
What could go wrong
This is an observational study that only develops and tests prediction models, not a treatment. The AI tools may not prove accurate enough for real-world use, and results may take years to validate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A total of 100 AAA patients and 100 PAD will be included per clinical center, with exeption for Asklepios Hamburg, they will solely include 100 PAD patients. This comes to a total of 1100 patients across 6 clinical centers in Europe.

Ages

40 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria AAA: * Males/females between 40 and 90 years of age. * Males and females with AAA at inclusion, any diameter \>3 cm (or 1.5x larger than their non-dilated part of the aorta). * Include: infrarenal, juxtarenal, pararenal, suprarenal abdominal aortic aneurysms. Exclusion Criteria AAA: Patients with: * Insufficient schooling or sensorial deficits that interfere understanding informed consent. * Not able to use the VASCUL-AID mobile health app (that will be provided in Dutch, English, German, Portuguese, Serbian, Finish, Swedish languages). * Proven or highly suspected for infected, mycotic AAA * Previous AAA surgery or planned for an AAA surgery within 6 months * Ruptured AAA Inclusion Criteria PAD: * Males/females between 40 and 90 years of age. * Patients with peripheral arterial disease stage Fontaine 2a and 2b at inclusion. Medical history (e.g. CLTI) does not matter, current disease stage is leading at inclusion. Exclusion Criteria PAD: Patients with: * Insufficient schooling or sensorial deficits that interfere understanding informed consent. * Not able to use the VASCUL-AID mobile health app (provided in Dutch, English, German, Portuguese, Serbian, Finnish, Swedish languages).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Abdominal aorta aneurism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal aortic aneurysm Disease Progression peripheral arterial disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Abdominal aorta aneurism Peripheral arterial disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.